中国神经再生研究(英文版) ›› 2018, Vol. 13 ›› Issue (4): 717-726.doi: 10.4103/1673-5374.230300

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

脑室内注射MPP和脑源性神经生长因子对海马结构、纹状体和黑质儿茶酚胺能神经末梢和神经发生的影响

  

  • 收稿日期:2017-12-20 出版日期:2018-04-15 发布日期:2018-04-15
  • 基金资助:

    国家自然科学基金(31320103906)

 Intracerebroventricularly-administered 1-methyl-4-phenylpyridinium ion and brain-derived neurotrophic factor affect catecholaminergic nerve terminals and neurogenesis in the hippocampus, striatum and substantia nigra

Jun-Fang Chen, Man Wang, Ying-Han Zhuang, Thomas Behnisch   

  1. The Institutes of Brain Science, the State Key Laboratory of Medical Neurobiology, and the Collaborative Innovation Center for Brain Science,Fudan University, Shanghai, China
  • Received:2017-12-20 Online:2018-04-15 Published:2018-04-15
  • Contact: Thomas Behnisch, Ph.D.,behnish@fudan.edu.cn
  • Supported by:

    This study was supported by the National Natural Science Foundation of China, No. 31320103906 (to TB)

摘要:

帕金森病是位于黑质纹状体等脑区的多巴胺能神经元发生不可逆死亡导致的神经退行性疾病。MPTP及体内活性代谢物MPP+可以调控多巴胺能神经元的生理活动,造成多巴胺能神经元的死亡,引起与帕金森病类似的症状,因而已成为构建帕金森病动物模型的常用药物。然而,MPP+侧脑室给药是否影响黑质和海马齿状回颗粒下层的神经发生,以及脑源性神经营养因子是否可以产生改变MPP+对神经发生活动的影响效应,这些问题目前仍未完全解决。为此,实验将MPP+(100 nmol)注射到成年小鼠脑部侧脑室建立帕金森病模型,发现给药7天后海马齿状回颗粒下层区域BrdU阳性染色信号增多,而在黑质区域减少,表明海马齿状回颗粒下层区域神经发生活动增强,而黑质区域的神经发生活动减弱;在MPP+给药第1天时,侧脑室注射脑源性神经生长因子(100 ng),发现注射后减弱了MPP+对海马齿状回颗粒下层区域及黑质区域神经发生活动的影响。结果表明,神经营养因子和神经毒素在帕金森病动物模型中表现出复杂的相互作用,对儿茶酚胺系统和不同脑区的神经发生造成了显著的影响。MPP+对帕金森病小鼠黑质和海马齿状回颗粒下层的神经发生产生显著影响,脑源性神经生长因子可减弱MPP+的效应。

orcid:0000-0002-7842-3252(Thomas Behnisch)

关键词: 帕金森病, MPTP, BDNF, 脑室灌注, 多巴胺能纤维, 去甲肾上腺素, 酪氨酸羟化酶, 海马, 黑质, 纹状体, 神经发生, 神经生长因子

Abstract:

Parkinson’s disease is a progressive neurological disease characterized by the degeneration of dopaminergic neurons in the substantia nigra. A highly similar pattern of neurodegeneration can be induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 1-methyl-4-phenylpyridinium ion (MPP+), which cause the death of dopaminergic neurons. Administration of MPTP or MPP+ results in Parkinson’s disease-like symptoms in rodents. However, it remains unclear whether intracerebroventricular MPP+ administration affects neurogenesis in the substantia nigra and subgranular zone or whether brain-derived neurotrophic factor alters the effects of MPP+. In this study, MPP+ (100 nmol) was intracerebroventricularly injected into mice to model Parkinson’s disease. At 7 days after administration, the number of bromodeoxyuridine (BrdU)-positive cells in the subgranular zone of the hippocampal dentate gyrus increased, indicating enhanced neurogenesis. In contrast, a reduction in BrdU-positive cells was detected in the substantia nigra. Administration of brain-derived neurotrophic factor (100 ng) 1 day after MPP+ administration attenuated the effect of MPP+ in the subgranular zone and the substantia nigra. These findings reveal the complex interaction between neurotrophic factors and neurotoxins in the Parkinsonian model that result in distinct effects on the catecholaminergic system and on neurogenesis in different brain regions.

Key words: nerve regeneration, Parkinson’s disease, MPTP, brain-derived neurotrophic factor, intracerebroventricular infusion, dopaminergic fibers, norepinephrine, tyrosine hydroxylase, hippocampus, substantia nigra, striatum, neurogenesis, neural regeneration